Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Int J Pharm ; 476(1-2): 9-15, 2014 Dec 10.
Artigo em Inglês | MEDLINE | ID: mdl-25245548

RESUMO

The purpose of this study was to develop vitamin E-based micelles loaded with Doxorubicin (DOX) (DOX-TOS-TPGS), taking advantages of the anti-cancer activity of vitamin E derivatives: Tocopherol succinate (TOS) and D-α-tocopherol polyethylene2000 succinate (TPGS). Therefore, we developed micelles consisting in a mixture of TOS (as solubilizer) and TPGS2000 (as stabilizer) (1:1). DOX-TOS-TPGS micelles exhibited a size of 78 nm and a ζ potential of -7 mV. High drug loading (40% w/w) was achieved. The critical micellar concentration was determined at 14 µg/ml. In vitro, after 24 h, DOX-TOS-TPGS micelles exhibited higher cytotoxicity than free-DOX (IC50 on MCF-7 cells, at 24 h, 58 vs 5 µg/ml). In vivo anti-tumor efficacy, performed on two tumor models (CT26 and MCF-7), demonstrated a 100% long-term survival of mice when treated with DOX-TOS-TPGS compared to DOX-free. Interestingly, the survival time of mice treated with unloaded TOS-TPGS micelles was similar to DOX-free, indicating an anti-cancer activity of vitamin E derivatives. Based on these results, it can be concluded that the formulations developed in this work may be considered as an effective DOX delivery system for cancer chemotherapy.


Assuntos
Antibióticos Antineoplásicos/farmacologia , Doxorrubicina/farmacologia , Sistemas de Liberação de Medicamentos , Vitamina E/análogos & derivados , Animais , Antibióticos Antineoplásicos/administração & dosagem , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Linhagem Celular Tumoral , Neoplasias do Colo/tratamento farmacológico , Neoplasias do Colo/patologia , Doxorrubicina/administração & dosagem , Excipientes/química , Feminino , Humanos , Concentração Inibidora 50 , Células MCF-7 , Camundongos , Camundongos Nus , Micelas , Polietilenoglicóis/química , Taxa de Sobrevida , Vitamina E/química , alfa-Tocoferol/química
2.
J Control Release ; 182: 33-44, 2014 May 28.
Artigo em Inglês | MEDLINE | ID: mdl-24631865

RESUMO

This review aims to highlight the development of novel vitamin E conjugates for the vectorization of active pharmaceutical ingredients through nanotechnologies. The physico-chemical and biological properties of vitamin E derivatives offer multiple advantages in drug delivery like biocompatibility, improvement of drug solubility and anticancer activity. Nanomedicines have shown high potential in drug delivery since (i) they may offer better drug biopharmaceutical properties such as longer half-life or better bioavailability and (ii) they have shown benefits in cancer therapy by improving anticancer drug therapeutic index. Vitamin E-based nanomedicines were developed to combine the pharmaceutical properties of both vitamin E and nanomedicines for two purposes: (i) to improve water solubility of hydrophobic drugs and (ii) to enhance the therapeutic efficiency of anticancer agents. This review is divided into three parts: the first one describes the biology and the metabolic functions of vitamin E, the second one focuses on the anticancer activity of two vitamin E derivatives: vitamin E succinate (TOS) and vitamin E polyethylene glycol-succinate (TPGS). Finally, in the third part, we discuss vitamin E derivatives based-nanomedicines.


Assuntos
Antineoplásicos/administração & dosagem , Sistemas de Liberação de Medicamentos , Vitamina E/administração & dosagem , Animais , Antineoplásicos/química , Humanos , Nanomedicina , Neoplasias/tratamento farmacológico , Vitamina E/química
3.
Bioconjug Chem ; 25(1): 72-81, 2014 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-24328289

RESUMO

Self-assembled prodrugs forming nanoaggregates are a promising approach to enhance the antitumor efficacy and to reduce the toxicity of anticancer drugs. To achieve this goal, doxorubicin was chemically conjugated to d-α-tocopherol succinate through an amide bond to form N-doxorubicin-α-d-tocopherol succinate (N-DOX-TOS). The prodrug self-assembled in water into 250 nm nanostructures when stabilized with d-α-tocopherol poly(ethylene glycol) 2000 succinate. Cryo-TEM analysis revealed the formation of nanoparticles with a highly ordered lamellar inner structure. NMR spectra of the N-DOX-TOS nanoparticles indicated that N-DOX-TOS is located in the core of the nanoparticles while PEG chains and part of the tocopherol are in the corona. High drug loading (34% w/w) and low in vitro drug release were achieved. In vitro biological assessment showed significant anticancer activity and temperature-dependent cellular uptake of N-DOX-TOS nanoparticles. In vivo, these nanoparticles showed a greater antitumor efficacy than free DOX. N-DOX-TOS nanoparticles might have the potential to improve DOX-based chemotherapy.


Assuntos
Antineoplásicos/farmacologia , Doxorrubicina/farmacologia , Sistemas de Liberação de Medicamentos , Neoplasias Experimentais/tratamento farmacológico , Pró-Fármacos/farmacologia , alfa-Tocoferol/farmacologia , Animais , Antineoplásicos/síntese química , Antineoplásicos/química , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Relação Dose-Resposta a Droga , Doxorrubicina/química , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Células MCF-7 , Camundongos , Camundongos Endogâmicos BALB C , Estrutura Molecular , Nanoestruturas/química , Neoplasias Experimentais/patologia , Pró-Fármacos/síntese química , Pró-Fármacos/química , Relação Estrutura-Atividade , alfa-Tocoferol/química
4.
Int J Pharm ; 423(2): 452-60, 2012 Feb 28.
Artigo em Inglês | MEDLINE | ID: mdl-22212463

RESUMO

The aim of this study was to develop tocol derivatives of chitosan able (i) to self-assemble in the gastrointestinal tract and (ii) to enhance the solubility of poorly soluble drugs. Among the derivatives synthesized, tocopherol succinate glycol chitosan (GC-TOS) conjugates spontaneously formed micelles in aqueous solution with a critical micelle concentration of 2 µg mL(-1). AFM and TEM analysis showed that spherical micelles were formed. The GC-TOS increased water solubility of 2 model class II drugs. GC-TOS loading efficiency was 2.4% (w/w) for ketoconazole and 0.14% (w/w) for itraconazole, respectively. GC-TOS was non-cytotoxic at concentrations up to 10 mg mL(-1). A 3.4-fold increase of the apparent permeation coefficient of ketoconazole across a Caco-2 cell monolayer was demonstrated. Tocol polymer conjugates may be promising vehicles for the oral delivery of poorly soluble drugs.


Assuntos
Quitosana/química , Portadores de Fármacos , Itraconazol/química , Cetoconazol/química , Tocoferóis/química , Administração Oral , Células CACO-2 , Sobrevivência Celular/efeitos dos fármacos , Química Farmacêutica , Quitosana/toxicidade , Relação Dose-Resposta a Droga , Composição de Medicamentos , Humanos , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/metabolismo , Itraconazol/administração & dosagem , Itraconazol/metabolismo , Cetoconazol/administração & dosagem , Cetoconazol/metabolismo , Cinética , Micelas , Microscopia de Força Atômica , Microscopia Eletrônica de Transmissão , Tamanho da Partícula , Permeabilidade , Solubilidade , Propriedades de Superfície , Tecnologia Farmacêutica/métodos , Tocoferóis/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA